Chronic Ethanol Consumption Inhibits Glucokinase Transcriptional Activity by Atf3 and Triggers Metabolic Syndrome in Vivo*

  1. Won-Ho Kim1
  1. From the Division of Metabolic Disease, Center for Biomedical Science,
  2. §Division of Structural and Functional Genomics, Center for Genomic Science, National Institutes of Health, Osong-eup, Cheongwon-gun, Chungbuk 363-951, Korea,
  3. the Departments of **Psychiatry and
  4. ‡‡Endocrinology, College of Medicine, Catholic University, Bucheon 420-743, Korea,
  5. the §§Department of Anatomy and Neurobiology, Institute of Health Sciences, Gyeongsang National University, Jinju, Gyeongnam 660-751, Korea,
  6. the Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea,
  7. the Division of Cardiology, Department of Internal Medicine, Chungbuk National University School of Medicine, Cheongju 361-763, Korea, and
  8. the ¶¶Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892
  1. 1 To whom correspondence should be addressed: Division of Metabolic Diseases, Center for Biomedical Sciences, National Institutes of Health, 187 Osong Saengmyeong2-ro, Osong-eup, Cheongwon-gun, Chungbuk, 363-951, Korea. Tel.: 82-43-719-8691; Fax: 82-43-719-9602; E-mail: jhkwh{at}nih.go.kr.

Background: Chronic ethanol consumption induces pancreatic β-cell dysfunction and metabolic syndrome.

Results: Ethanol-induced Atf3 inhibits glucokinase transcriptional activity through direct binding or Atf3/Pdx-1/Hdac1 axis on glucokinase promoter.

Conclusion: ATf3 fosters β-cell dysfunction via Gck down-regulation and triggers T2D, which is ameliorated by in vivo Atf3 silencing.

Significance: The presented data uncover a new role for Atf3 as a potential therapeutic target in treating type 2 diabetes.

Abstract

Chronic ethanol consumption induces pancreatic β-cell dysfunction through glucokinase (Gck) nitration and down-regulation, leading to impaired glucose tolerance and insulin resistance, but the underlying mechanism remains largely unknown. Here, we demonstrate that Gck gene expression and promoter activity in pancreatic β-cells were suppressed by chronic ethanol exposure in vivo and in vitro, whereas expression of activating transcription factor 3 (Atf3) and its binding to the putative Atf/Creb site (from −287 to −158 bp) on the Gck promoter were up-regulated. Furthermore, in vitro ethanol-induced Atf3 inhibited the positive effect of Pdx-1 on Gck transcriptional regulation, enhanced recruitment of Hdac1/2 and histone H3 deacetylation, and subsequently augmented the interaction of Hdac1/Pdx-1 on the Gck promoter, which were diminished by Atf3 siRNA. In vivo Atf3-silencing reversed ethanol-mediated Gck down-regulation and β-cell dysfunction, followed by the amelioration of impaired glucose tolerance and insulin resistance. Together, we identified that ethanol-induced Atf3 fosters β-cell dysfunction via Gck down-regulation and that its loss ameliorates metabolic syndrome and could be a potential therapeutic target in treating type 2 diabetes. The Atf3 gene is associated with the induction of type 2 diabetes and alcohol consumption-induced metabolic impairment and thus may be the major negative regulator for glucose homeostasis.

Footnotes

  • * This work was authored, in whole or in part, by National Institutes of Health staff. This work was supported by Research Grant 4845-302-210-13 from the Korean National Institutes of Health.

  • Received June 2, 2014.
  • Revision received July 27, 2014.

Author's Choice—Final version full access.

Creative Commons Attribution Unported License applies to Author Choice Articles

Table of Contents
AUTHOR'S CHOICE

This Article

  1. The Journal of Biological Chemistry 289, 27065-27079.
  1. Free via Open Access: OA
  2. Free via Creative Commons: CC-BY license
  3. All Versions of this Article:
    1. M114.585653v1
    2. 289/39/27065 (most recent)

Article Usage Stats

Submit your work to JBC.

You'll be in good company.